triazoles has been researched along with Blast Phase in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreeff, M; Baz, R; Carlson, R; Gabrail, N; Garzon, R; Gutierrez, M; Kashyap, T; Kauffman, M; Klebanov, B; Mau-Sorensen, PM; Rashal, T; Saint-Martin, JR; Savoie, L; Savona, M; Shacham, S; Stone, R; Unger, TJ; Wagner-Johnston, N; Yee, K | 1 |
| Burnett, AK; Hills, R; Lazenby, M; Zabkiewicz, J | 1 |
| Bhagwat, AS; Hohmann, AF; Mok, BYL; Roe, JS; Shi, J; Vakoc, CR | 1 |
| Baloglu, E; Berezovskaya, A; Conway, AS; Etchin, J; Galinsky, IA; Kauffman, M; Landesman, Y; Look, AT; Senapedis, W; Shacham, S; Stone, RM; Wang, JC | 1 |
1 trial(s) available for triazoles and Blast Phase
| Article | Year |
|---|---|
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Topics: Adult; Blast Crisis; Bone Marrow Cells; Disease-Free Survival; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Triazoles | 2017 |
3 other study(ies) available for triazoles and Blast Phase
| Article | Year |
|---|---|
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Female; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Male; Proto-Oncogene Proteins c-akt; Triazoles | 2015 |
BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements.
Topics: Animals; Azepines; Blast Crisis; Cell Differentiation; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Genome; Leukemia, Myeloid, Acute; Mediator Complex; Mice; Nuclear Proteins; Protein Subunits; Regulatory Sequences, Nucleic Acid; RNA Polymerase II; Transcription Factors; Transcription, Genetic; Triazoles | 2016 |
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Blast Crisis; Carcinogenesis; Exportin 1 Protein; Hematopoietic Stem Cells; Heterografts; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Receptors, Cytoplasmic and Nuclear; Triazoles | 2017 |